Etana Biotechnologies

Executive Summary

Etana Biotechnologies Indonesia is a private biopharmaceutical company founded in 2014, headquartered in Seongnam, South Korea, with operations focused on Indonesia. The company develops and commercializes affordable, high-quality biosimilars and recombinant protein therapeutics addressing metabolic, autoimmune, and oncology indications. Its lead marketed product is RENOGEN (Epoetin Alfa) for anemia, and it is preparing to launch BEVAGEN, a bevacizumab biosimilar for oncology. Etana is also building in-house capabilities for monoclonal antibody production to expand its pipeline. As a commercial-stage company with limited public disclosure, Etana operates in the growing Southeast Asian biosimilar market, where it aims to increase access to biologic therapies. Its near-term prospects hinge on successful commercialization of BEVAGEN and advancement of its manufacturing infrastructure, though financial details and pipeline depth remain opaque.

Upcoming Catalysts (preview)

• Q2 2026BEVAGEN (bevacizumab biosimilar) launch in Indonesia80% success
• Q4 2026Completion of monoclonal antibody manufacturing facility70% success
• TBDPotential partnership or licensing deal for ex-Indonesia distribution40% success